Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Biomea Fusion(US:BMEA) Seeking Alpha·2026-01-15 07:35Company Overview - Biomea Fusion is currently developing two significant assets focused on diabetes and obesity [3] Product Development - The first asset, Icovamenib, is an oral small molecule specifically targeted at diabetes [4] - The company has reported data from the Covalent 111 study, highlighting significant activity in two patient populations [4]